Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., established in 2000 and based in Tel Aviv-Yafo, Israel, is a clinical-stage biopharmaceutical company dedicated to developing therapeutics for liver diseases. Its primary focus is on Aramchol, an oral therapy currently undergoing a Phase III pivotal study called ARREST for treating non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have pre-diabetes or type-II diabetes mellitus. Additionally, Galmed is evaluating Aramchol through the ARRIVE Study, a proof-of-concept Phase IIa clinical trial, for HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company has research agreements to develop combination therapies and identify microbiome repertoires associated with Aramchol's response.